4587 Stock Overview
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
PeptiDream Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥2,467.50 |
52 Week High | JP¥2,929.00 |
52 Week Low | JP¥1,039.00 |
Beta | 0.58 |
11 Month Change | 13.40% |
3 Month Change | 12.36% |
1 Year Change | 45.58% |
33 Year Change | -36.32% |
5 Year Change | -54.31% |
Change since IPO | 243.30% |
Recent News & Updates
PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 29PeptiDream Inc. Just Beat Revenue Estimates By 13%
Aug 12Recent updates
PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 29PeptiDream Inc. Just Beat Revenue Estimates By 13%
Aug 12PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Jun 30News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Jun 02PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
Apr 30Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Apr 29PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
Mar 03Shareholder Returns
4587 | JP Biotechs | JP Market | |
---|---|---|---|
7D | -2.2% | 0.7% | -0.9% |
1Y | 45.6% | 5.7% | 4.9% |
Return vs Industry: 4587 exceeded the JP Biotechs industry which returned 6.4% over the past year.
Return vs Market: 4587 exceeded the JP Market which returned 6.8% over the past year.
Price Volatility
4587 volatility | |
---|---|
4587 Average Weekly Movement | 9.6% |
Biotechs Industry Average Movement | 13.6% |
Market Average Movement | 6.4% |
10% most volatile stocks in JP Market | 10.3% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4587 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4587's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 745 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.
PeptiDream Inc. Fundamentals Summary
4587 fundamental statistics | |
---|---|
Market cap | JP¥319.82b |
Earnings (TTM) | JP¥21.69b |
Revenue (TTM) | JP¥55.42b |
14.7x
P/E Ratio5.8x
P/S RatioIs 4587 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4587 income statement (TTM) | |
---|---|
Revenue | JP¥55.42b |
Cost of Revenue | JP¥12.20b |
Gross Profit | JP¥43.22b |
Other Expenses | JP¥21.53b |
Earnings | JP¥21.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
Earnings per share (EPS) | 167.34 |
Gross Margin | 77.98% |
Net Profit Margin | 39.14% |
Debt/Equity Ratio | 35.6% |
How did 4587 perform over the long term?
See historical performance and comparison